Literature DB >> 26788739

Malignant melanoma (non-metastatic): sentinel lymph node biopsy.

Andy Pay1.   

Abstract

INTRODUCTION: The incidence of malignant melanoma has increased over the past 25 years in the UK, but death rates have remained fairly constant. The 5-year survival rate ranges from 20% to 95%, depending on disease stage. Risks are greater in white populations and in people with higher numbers of skin naevi. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical question: What is the evidence for performing a sentinel lymph node biopsy in people with malignant melanoma with clinically uninvolved lymph nodes? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview).
RESULTS: At this update, searching of electronic databases retrieved 221 studies. After deduplication and removal of conference abstracts, 99 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 58 studies and the further review of 41 full publications. Of the 41 full articles evaluated, one systematic review and three RCTs were added at this update. We performed a GRADE evaluation for two PICO combinations.
CONCLUSIONS: In this systematic overview, we evaluated the evidence for performing sentinel lymph node biopsy in people with malignant melanoma with clinically uninvolved lymph nodes.

Entities:  

Mesh:

Year:  2016        PMID: 26788739      PMCID: PMC4720216     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  14 in total

1.  Sentinel node biopsy for malignant melanoma. Having this biopsy gives psychological benefits.

Authors:  S S Rayatt; S Hettiaratchy; A Key; B W Powell
Journal:  BMJ       Date:  2000-11-18

2.  Melanoma: summary of NICE guidance.

Authors:  Fergus Macbeth; Julia Newton-Bishop; Susan O'Connell; James E Hawkins
Journal:  BMJ       Date:  2015-07-29

3.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Cyril Konto; Axel Hoos; Veerle de Pril; Ravichandra Karra Gurunath; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  Lancet Oncol       Date:  2015-03-31       Impact factor: 41.316

4.  Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.

Authors:  Christopher K Bichakjian; Allan C Halpern; Timothy M Johnson; Antoinette Foote Hood; James M Grichnik; Susan M Swetter; Hensin Tsao; Victoria Holloway Barbosa; Tsu-Yi Chuang; Madeleine Duvic; Vincent C Ho; Arthur J Sober; Karl R Beutner; Reva Bhushan; Wendy Smith Begolka
Journal:  J Am Acad Dermatol       Date:  2011-08-25       Impact factor: 11.527

5.  The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).

Authors:  Mark B Faries; John F Thompson; Alistair Cochran; Robert Elashoff; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-Jing Wang; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2010-07-08       Impact factor: 5.344

Review 6.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

8.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

Review 9.  Dilemma of clinically node-negative head and neck melanoma: outcome of "watch and wait" policy, elective lymph node dissection, and sentinel node biopsy--a systematic review.

Authors:  Pieter J Tanis; Omgo E Nieweg; Michiel W M van den Brekel; Alfons J M Balm
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

10.  Comparison between F-Fluorodeoxyglucose Positron Emission Tomography and Sentinel Lymph Node Biopsy for Regional Lymph Nodal Staging in Patients with Melanoma: A Review of the Literature.

Authors:  Paoletta Mirk; Giorgio Treglia; Marco Salsano; Pietro Basile; Alessandro Giordano; Lorenzo Bonomo
Journal:  Radiol Res Pract       Date:  2011-12-22
View more
  2 in total

Review 1.  Oncolytic Viruses for the Treatment of Metastatic Melanoma.

Authors:  Megan H Trager; Larisa J Geskin; Yvonne M Saenger
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

2.  Prognostic factors and population-based analysis of melanoma with sentinel lymph node biopsy.

Authors:  Ping-Chung Wu; Yu-Ching Chen; Hsiu-Min Chen; Lee-Wei Chen
Journal:  Sci Rep       Date:  2021-10-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.